Perlegen Sciences
Newark
About Perlegen Sciences
Perlegen Sciences engages in the discovery and commercialization of genetic variations that provide physicians with information to improve the clinical decision-making process and patient treatment outcomes. Its products include MammaPLUS, a breast cancer risk stratifier and a panel of common genetic variants that stratifies individual genetic and background/clinical risk for those at moderately elevated risk for non-familial breast cancer, as well as impacts the risk for developing invasive breast cancer; and Genotype Browser Website that provides a way to access and view the results of a study of genetic variation in various diverse human populations. Perlegen Sciences, Inc. was founded in 2000 and is based in Mountain View, California.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $154.0M
- Funding stage: Late Stage Venture
- Last round: Series D (Jan 2006)
- Website: perlegen.com
Industries & Categories
Biotechnology, Genetics, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/perlegen-sciences-2614956 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.